Ranbaxy commercialises Isoptin®Sr in US

RELATED NEWS Ranbaxy Lab has support at Rs 325-335: Bhambwani Remain invested in Ranbaxy Lab Valtrex patent settlement +ve for Ranbaxy stock Ranbaxy settles patent dispute with GSK on Valacyclovir ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 10/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (RLL), today announced the commercialization of its first Authorized Generic (AG) product, Isoptin® SR (Verapamil SR) in the US market, through its wholly owned subsidiary, Ranbaxy Pharmaceuticals Inc. (RPI), following an agreement with FSC Laboratories, Inc. of Charlotte, North Carolina, USA. 

 

Commenting on the development, K Venkatachalam,Vice President & Regional Director, North America, Ranbaxy, said, "The commercialization of Isoptin® SR heralds Ranbaxy's entry into the Authorised Generics space. Isoptin® SR, a niche value added formulation, also enhances our New Drug Delivery systems (NDDS) capability and our efforts with other molecules, to improve patient compliance."    

 

Verapamil, a calcium ion antagonist or channel blocker, is indicated for the management of hypertension and angina.  The generic market for Verapamil SR is worth  $122.2 million  (IMS - MAT: December 2006) with limited competition primarily from 2 other players.

 

Sourced From: Ranbaxy Laboratories Ltd